IBUPAS 136 MG MEDICATED PATCH 7 PATCHES

Name
IBUPAS 136 mg medicated patch
Ibuprofen


What it is and what it is used for
IBUPAS is a pharmaceutical formulation containing ibuprofen as the active ingredient, a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic action, which is released transdermally.

IBUPAS is indicated for the local treatment of rheumatic and traumatic pain and inflammation of the joints, muscles, tendons and ligaments.


What you need to know before taking the medicine
Do not use IBUPAS
- If you are allergic to the active substance or any of the excipients.
- On open wounds or lesions, but only on intact skin. Avoid contact with eyes and mucous membranes.
- If you have had a hypersensitivity episode (asthma, allergic rhinitis, skin rashes and anaphylactic reactions) or gastrointestinal bleeding from anti-inflammatory drugs in the past.
- In the presence of an active peptic ulcer, if you have bronchial asthma or are undergoing anticoagulant therapy.
- If you are in the last 3 months of pregnancy and are breastfeeding.
- In children under 12 years of age.
- In case of severe heart failure.
- In case of severe renal or hepatic insufficiency.


Warnings and precautions
Take special care with IBUPAS
Analgesics, antipyretics, nonsteroidal anti-inflammatory drugs, including ibuprofen, can cause hypersensitivity reactions, potentially serious even in subjects not previously exposed to this type of drug.
Serious skin reactions including exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) have been reported in association with ibuprofen treatment. Stop using IBUPAS and contact your doctor immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.

IBUPAS must be used with great caution and on the advice of a doctor:
• In the elderly,
• In patients with chronic bronchitis, allergic rhinitis or inflammation of the nasal mucosa (in whom asthmatic attacks or severe inflammatory reactions of the skin and mucosa are more frequent),
• In patients with a history of gastrointestinal disease (such as gastrointestinal ulcer, ulcerative colitis or Crohn's disease),
• In patients with a history of gastrointestinal bleeding even if not caused by the administration of NSAIDs or with other bleeding disorders,
• In patients with liver or kidney dysfunction or heart failure,
• If you suffer or have suffered from high blood pressure.


Possible side effects
Like all medicines, IBUPAS can cause side effects, although not everybody gets them.

The frequency of the possible side effects listed below is established using the following convention:
Very common ≥1/10; Common ≥1/100 - <1/10; Uncommon ≥1/1,000 - <1/100; Rare ≥1/10,000 - <1/1,000; Very rare <1/10,000; not known (cannot be estimated from the available data).

In controlled clinical studies on this product the following adverse effects have been observed:

Nervous system disorders
Common: Dry mouth, headache, taste disturbance

Gastrointestinal disorders
Common: Nausea

Skin and subcutaneous tissue disorders
Common: Facial edema, blisters
Not known: the skin becomes sensitive to light

Musculoskeletal and connective tissue disorders
Common: General malaise

Systemic disorders and conditions related to the administration site
Very Common: Mild skin redness or modest irritation at the application site, which rapidly regress after the medicated plaster is removed.
Common: Itching, burning, obvious skin irritation with redness of the skin, skin peeling and small skin lesions.

All adverse effects observed in clinical studies were mild and transient in nature.

In the literature data, the following adverse effects have been reported:

Immune system disorders
Not known: Local hypersensitivity

Systemic disorders and conditions related to the administration site
Not known: Contact dermatitis, numbness and tingling at the application site

Rare cases of extensive and severe dermatological lesions such as Quincke's edema and, very rarely, bullous reactions have also been reported with this type of medicine.

Stop using IBUPAS and consult your doctor immediately if you notice any of the following symptoms:
• flat, target-shaped or circular reddish spots on the trunk, often with central blisters, peeling skin, and ulcers of the mouth, throat, nose, genitals, and eyes. These severe rashes may be preceded by fever and flu-like symptoms [exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis].
• Widespread skin rash, high body temperature, swollen lymph nodes, and increased eosinophils, a type of white blood cell (DRESS syndrome).
• Widespread, red, scaly rash with bumps under the skin and blisters, accompanied by fever. Symptoms usually appear at the start of treatment (acute generalized exanthematous pustulosis).

Systemic adverse reactions following topical use of ibuprofen are unlikely since the plasma levels of ibuprofen detected following the application of IBUPAS are much lower than those detectable with the systemic administration of ibuprofen-based drugs. However, following applications for long periods of time, beyond the recommended term and failure to observe contraindications and warnings, the appearance of systemic adverse effects, especially at the gastrointestinal level, cannot be excluded.
Following the instructions in the package leaflet reduces the risk of side effects.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system at: https://www.aifa.gov.it/content/segnalazionireazioni-avverse .
By reporting side effects you can help provide more information on the safety of this medicine.